JP2017508970A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508970A5
JP2017508970A5 JP2016556777A JP2016556777A JP2017508970A5 JP 2017508970 A5 JP2017508970 A5 JP 2017508970A5 JP 2016556777 A JP2016556777 A JP 2016556777A JP 2016556777 A JP2016556777 A JP 2016556777A JP 2017508970 A5 JP2017508970 A5 JP 2017508970A5
Authority
JP
Japan
Prior art keywords
biomarker
biological sample
time point
psa
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016556777A
Other languages
English (en)
Japanese (ja)
Other versions
JP6625061B2 (ja
JP2017508970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2015/050272 external-priority patent/WO2015137870A1/en
Publication of JP2017508970A publication Critical patent/JP2017508970A/ja
Publication of JP2017508970A5 publication Critical patent/JP2017508970A5/ja
Application granted granted Critical
Publication of JP6625061B2 publication Critical patent/JP6625061B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016556777A 2014-03-11 2015-03-11 固形腫瘍癌を検出する方法 Expired - Fee Related JP6625061B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1450274 2014-03-11
SE1450274-4 2014-03-11
SE1450420-3 2014-04-04
SE1450420 2014-04-04
PCT/SE2015/050272 WO2015137870A1 (en) 2014-03-11 2015-03-11 Method for detecting a solid tumor cancer

Publications (3)

Publication Number Publication Date
JP2017508970A JP2017508970A (ja) 2017-03-30
JP2017508970A5 true JP2017508970A5 (enExample) 2018-04-19
JP6625061B2 JP6625061B2 (ja) 2019-12-25

Family

ID=52829276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016556777A Expired - Fee Related JP6625061B2 (ja) 2014-03-11 2015-03-11 固形腫瘍癌を検出する方法

Country Status (9)

Country Link
US (1) US10451626B2 (enExample)
EP (2) EP4220170A3 (enExample)
JP (1) JP6625061B2 (enExample)
AU (2) AU2015230017B2 (enExample)
CA (2) CA2940445C (enExample)
DK (1) DK3117216T3 (enExample)
FI (1) FI3117216T3 (enExample)
RU (1) RU2720148C9 (enExample)
WO (1) WO2015137870A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6308954B2 (ja) 2012-03-05 2018-04-11 オサケユキテュア・アークティック・パートナーズ・アクチボラゲットOy Arctic Partners Ab 前立腺癌のリスク及び前立腺容積を予測する方法及び装置
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
CA2982262A1 (en) 2015-04-29 2016-11-03 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
US11479878B2 (en) 2016-03-16 2022-10-25 Dana-Farber Cancer Institute, Inc. Methods for genome characterization
EP3270163B1 (en) * 2016-07-15 2018-09-05 ProteoMediX AG Method of detecting proteins in human samples and uses of such methods
US20190345565A1 (en) * 2017-02-01 2019-11-14 Phadia Ab Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics
WO2018144678A1 (en) * 2017-02-03 2018-08-09 The Johns Hopkins University Mini-cancers utilization for personalized cancer drug regimens
RU2664706C2 (ru) * 2017-06-02 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ прогнозирования клинического статуса рака предстательной железы
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
WO2020205204A1 (en) * 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
IT202000029948A1 (it) * 2020-12-04 2022-06-04 Nib Biotec S R L Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età
KR20250107193A (ko) * 2022-10-27 2025-07-11 마이옴, 인크. 다수의 데이터 소스들을 조합하여 질병들의 조기 검출을 하기 위한 접근법
WO2024092136A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center Machine learning modeling for inpatient prediction

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219840A1 (en) 2002-05-24 2003-11-27 Mikolajczyk Stephen D. Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection
US20050277137A1 (en) 2003-08-15 2005-12-15 University Of Pittsburgh Diagnostic multimarker serological profiling
KR100830811B1 (ko) 2006-09-18 2008-05-20 충북대학교 산학협력단 종양표시인자 검출용 바이오센서
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
CA2750062A1 (en) 2009-01-19 2010-07-22 Katrin Stedronsky Diagnostic assays for prostate cancer using psp94 and psa biomarkers
US20120121618A1 (en) 2009-02-12 2012-05-17 Dana-Farber Cancer Institute, Inc. Predicting And Treating Prostate Cancer
EP2407555A1 (en) * 2010-07-14 2012-01-18 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Methods and kits for the diagnosis of prostate cancer
EP2611943B1 (en) 2010-09-03 2017-01-04 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
AU2011352167A1 (en) * 2010-12-28 2013-07-11 Caris Mpi, Inc. Molecular profiling for cancer
CA2799163C (en) 2011-12-18 2025-01-07 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
EP2850432A2 (en) * 2012-05-16 2015-03-25 Phadia AB Method for indicating the presence or non-presence of prostate cancer
RU2669809C2 (ru) * 2012-11-20 2018-10-16 Пхадиа Аб Способ прогноза для индивидуумов с раком предстательной железы
MY182773A (en) 2012-11-20 2021-02-05 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer

Similar Documents

Publication Publication Date Title
AU2021232712B2 (en) Method for detecting a solid tumor cancer
Rubinstein et al. Cancer screening with multicancer detection tests: a translational science review
Rozeman et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
Abbosh et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
JP7228896B2 (ja) 乳がん患者の予後の予測方法
JP2018505658A5 (enExample)
JP2015524052A (ja) 前立腺癌の存在または不存在の提示方法
JP2016508026A5 (enExample)
KR20250010581A (ko) 단편화 프로파일을 사용한 암 모니터링 방법
Kanyong et al. Immunochemical assays and nucleic-acid detection techniques for clinical diagnosis of prostate cancer
WO2025201509A1 (zh) 获得癌症风险预测标志物的方法以及癌症风险评估方法
JP2020505928A (ja) 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
TWI507412B (zh) Gastric cancer biological markers and their use, as well as gastric cancer-related detection methods
JP6612509B2 (ja) 大腸癌の予後診断を補助する方法、記録媒体および判定装置
CN116013525A (zh) 一种基于铁死亡特征构建的结直肠癌预后模型及其构建方法
JP2017029058A (ja) チロシンキナーゼ融合遺伝子の検出法
CN106932580B (zh) Hsp90AB1蛋白在预测肺癌预后风险的诊断模型中的应用
WO2007030919A1 (en) Molecular method for diagnosis of prostate cancer
CN121747935A (zh) 基于棕榈酰化相关lncRNA的结直肠癌多靶点预后风险评估模型构建方法
CN117844924A (zh) 肾细胞癌的生物标志物bub1
CN120544673A (zh) 一种基于双硫死亡相关基因的胶质瘤预后风险预测模型及其应用
Loertzer et al. PSA quick test in capillary blood
CN117524468A (zh) 一种肝细胞癌预后评估的标志物、模型及应用
CN121109589A (zh) eccDNA标志物及其在结直肠癌预后预测中的应用
KR20210127519A (ko) 진행성 유방암 환자의 예후 예측 방법